NCT07815574
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07815574
Title iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma (SCOPE Plus)
Acronym SCOPE Plus
Recruitment Not yet recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Scancell Ltd
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR